DE

504.5

-1.62%↓

FDX

236.86

-0.6%↓

PAYX

144.88

+0.35%↑

CPRT

47.55

-2.1%↓

HEICO

317.18

-0.37%↓

DE

504.5

-1.62%↓

FDX

236.86

-0.6%↓

PAYX

144.88

+0.35%↑

CPRT

47.55

-2.1%↓

HEICO

317.18

-0.37%↓

DE

504.5

-1.62%↓

FDX

236.86

-0.6%↓

PAYX

144.88

+0.35%↑

CPRT

47.55

-2.1%↓

HEICO

317.18

-0.37%↓

DE

504.5

-1.62%↓

FDX

236.86

-0.6%↓

PAYX

144.88

+0.35%↑

CPRT

47.55

-2.1%↓

HEICO

317.18

-0.37%↓

DE

504.5

-1.62%↓

FDX

236.86

-0.6%↓

PAYX

144.88

+0.35%↑

CPRT

47.55

-2.1%↓

HEICO

317.18

-0.37%↓

Search

Ocugen Inc

Fermé

1.04 8.33

Résumé

Variation du prix de l'action

24h

Actuel

Min

0.96

Max

1.07

Chiffres clés

By Trading Economics

Revenu

-1.5M

-15M

Ventes

717K

1.5M

Marge bénéficiaire

-1,036.462

Employés

95

EBITDA

-350K

-14M

Recommandations

By TipRanks

Recommandations

Achat Fort

Prévisions sur 12 Mois

+552.58% upside

Dividendes

By Dow Jones

Prochains Résultats

7 août 2025

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

79M

283M

Ouverture précédente

-7.29

Clôture précédente

1.04

Score Technique

By Trading Central

Confiance

Strong Bearish Evidence

Ocugen Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

8 juil. 2025, 19:37 UTC

Principaux Mouvements du Marché
Acquisitions, Fusions, Rachats

M3-Brigade Shares Fall on Merger With ReserveOne

8 juil. 2025, 23:45 UTC

Market Talk

Gold Edges Lower, Weighed by Higher Treasury Yields -- Market Talk

8 juil. 2025, 23:42 UTC

Market Talk

Nikkei May Rise as Yen Weakens -- Market Talk

8 juil. 2025, 23:27 UTC

Market Talk

Australian REITs Yet to Offer Enough Appeal -- Market Talk

8 juil. 2025, 23:27 UTC

Market Talk

Global Equities Roundup: Market Talk

8 juil. 2025, 23:21 UTC

Market Talk

Summerset Bull Lauds Strong 2Q Sales Volumes -- Market Talk

8 juil. 2025, 23:21 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

8 juil. 2025, 22:29 UTC

Acquisitions, Fusions, Rachats

Capricorn to Pay A$1.5 Million in Cash and Shares

8 juil. 2025, 22:28 UTC

Acquisitions, Fusions, Rachats

Capricorn Metals Enters Binding Agreement to Buy Claw Gold Project

8 juil. 2025, 21:58 UTC

Market Talk

Kura Sushi Closely Watching U.S. Tariff Negotiations on Asian Goods -- Market Talk

8 juil. 2025, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

8 juil. 2025, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

8 juil. 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

8 juil. 2025, 20:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

8 juil. 2025, 19:53 UTC

Market Talk

Copper Posts Biggest One-Day Gain Ever to Hit Record on Tariff Chatter -- Market Talk

8 juil. 2025, 19:53 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

8 juil. 2025, 19:45 UTC

Market Talk

Canada Unlikely to Succeed in Bid for Tariff-Free Trade With U.S. -- Market Talk

8 juil. 2025, 19:29 UTC

Market Talk

U.S. Consumer-Credit Growth Slowed in May -- Market Talk

8 juil. 2025, 19:20 UTC

Market Talk

U.S. Natural Gas Futures Settle Lower -- Market Talk

8 juil. 2025, 19:11 UTC

Market Talk

Bank of Canada's Rate Cuts Deliver Muted Relief Along the Curve -- Market Talk

8 juil. 2025, 19:01 UTC

Market Talk

Oil Futures Gain With Support From Products -- Market Talk

8 juil. 2025, 18:49 UTC

Résultats

Hershey Names New CEO, Continuing Leadership Shuffle. The Stock Falls. -- Barrons.com

8 juil. 2025, 18:41 UTC

Market Talk

Mexico's Inflation Seen Mixed in June -- Market Talk

8 juil. 2025, 18:38 UTC

Market Talk

Gold Falls as Markets Digest Details of Trump Tariffs -- Market Talk

8 juil. 2025, 18:23 UTC

Market Talk

Analysts Anticipate Lower Ethanol Inventories -- Market Talk

8 juil. 2025, 18:10 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

8 juil. 2025, 18:10 UTC

Market Talk

Freeport-McMoRan Jumps on Trump Tariff Plan for Copper Imports -- Market Talk

8 juil. 2025, 17:24 UTC

Market Talk

Election, Dollar Seen as Potential Headwinds for Ibovespa -- Market Talk

8 juil. 2025, 17:06 UTC

Market Talk

KeyCorp and Regional Banks Set for a Catchup -- Market Talk

8 juil. 2025, 16:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

Comparaison

Variation de prix

Ocugen Inc prévision

Objectif de Prix

By TipRanks

552.58% hausse

Prévisions sur 12 Mois

Moyen 6.33 USD  552.58%

Haut 8 USD

Bas 4 USD

Basé sur 3 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

3 ratings

3

Achat

0

Maintien

0

Vente

Score Technique

By Trading Central

0.6818 / 0.74Support & Résistance

Court Terme

Strong Bearish Evidence

Moyen Terme

Strong Bullish Evidence

Long Terme

No Evidence

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Ocugen Inc

Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is also involved in the development of OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage, currently under Phase 3 studies indicated for the repair of knee cartilage injuries in adult. In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine. It has collaboration agreements with National Institute of Allergy and Infectious Diseases for early clinical studies for the OCU500 program; and a strategic partnership with CanSino Biologics Inc. for manufacturing its modifier gene therapy pipeline product candidates. The company was founded in 2013 and is headquartered in Malvern, Pennsylvania.